These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 22406119)

  • 1. Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease.
    Houston J; Smith K; Isakova T; Sowden N; Wolf M; Gutiérrez OM
    J Ren Nutr; 2013 Jan; 23(1):12-20. PubMed ID: 22406119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor 23 is associated with left ventricular hypertrophy, not with uremic vasculopathy in peritoneal dialysis patients.
    Sarmento-Dias M; Santos-Araújo C; Poínhos R; Oliveira B; Silva IS; Silva LS; Sousa MJ; Correia F; Pestana M
    Clin Nephrol; 2016 Mar; 85(3):135-41. PubMed ID: 26833300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
    Isakova T; Wahl P; Vargas GS; Gutiérrez OM; Scialla J; Xie H; Appleby D; Nessel L; Bellovich K; Chen J; Hamm L; Gadegbeku C; Horwitz E; Townsend RR; Anderson CA; Lash JP; Hsu CY; Leonard MB; Wolf M
    Kidney Int; 2011 Jun; 79(12):1370-8. PubMed ID: 21389978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary phosphorus restriction by a standard low-protein diet decreased serum fibroblast growth factor 23 levels in patients with early and advanced stage chronic kidney disease.
    Goto S; Nakai K; Kono K; Yonekura Y; Ito J; Fujii H; Nishi S
    Clin Exp Nephrol; 2014 Dec; 18(6):925-31. PubMed ID: 24578219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease.
    Isakova T; Gutiérrez OM; Smith K; Epstein M; Keating LK; Jüppner H; Wolf M
    Nephrol Dial Transplant; 2011 Feb; 26(2):584-91. PubMed ID: 20631407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function.
    Dhayat NA; Ackermann D; Pruijm M; Ponte B; Ehret G; Guessous I; Leichtle AB; Paccaud F; Mohaupt M; Fiedler GM; Devuyst O; Pechère-Bertschi A; Burnier M; Martin PY; Bochud M; Vogt B; Fuster DG
    Kidney Int; 2016 Sep; 90(3):648-57. PubMed ID: 27370409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.
    Mehta R; Ying GS; Houston S; Isakova T; Nessel L; Ojo A; Go A; Lash J; Kusek J; Grunwald J; Wolf M;
    Nephrol Dial Transplant; 2015 Sep; 30(9):1534-41. PubMed ID: 25910495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary phosphate excretion and fibroblast growth factor 23 in chronic kidney disease.
    Di Iorio BR; Torraca S; Sirico ML; Di Micco L
    J Ren Nutr; 2013 Sep; 23(5):e97-8. PubMed ID: 23131571
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of westernization on fibroblast growth factor 23 levels among individuals of African ancestry.
    Eckberg K; Kramer H; Wolf M; Durazo-Arvizu R; Tayo B; Luke A; Cooper R
    Nephrol Dial Transplant; 2015 Apr; 30(4):630-5. PubMed ID: 25358495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acid Load and Phosphorus Homeostasis in CKD.
    Khairallah P; Isakova T; Asplin J; Hamm L; Dobre M; Rahman M; Sharma K; Leonard M; Miller E; Jaar B; Brecklin C; Yang W; Wang X; Feldman H; Wolf M; Scialla JJ;
    Am J Kidney Dis; 2017 Oct; 70(4):541-550. PubMed ID: 28645705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consequences of a high phosphorus intake on mineral metabolism and bone remodeling in dependence of calcium intake in healthy subjects - a randomized placebo-controlled human intervention study.
    Trautvetter U; Jahreis G; Kiehntopf M; Glei M
    Nutr J; 2016 Jan; 15():7. PubMed ID: 26786148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorus Additives and Albuminuria in Early Stages of CKD: A Randomized Controlled Trial.
    Chang AR; Miller ER; Anderson CA; Juraschek SP; Moser M; White K; Henry B; Krekel C; Oh S; Charleston J; Appel LJ
    Am J Kidney Dis; 2017 Feb; 69(2):200-209. PubMed ID: 27865566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease.
    Zhang S; Gillihan R; He N; Fields T; Liu S; Green T; Stubbs JR
    Kidney Int; 2013 Oct; 84(4):713-21. PubMed ID: 23698235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic African Ancestry and Markers of Mineral Metabolism in CKD.
    Gutiérrez OM; Parsa A; Isakova T; Scialla JJ; Chen J; Flack JM; Nessel LC; Gupta J; Bellovich KA; Steigerwalt S; Sondheimer JH; Wright JT; Feldman HI; Kusek JW; Lash JP; Wolf M
    Clin J Am Soc Nephrol; 2016 Apr; 11(4):653-62. PubMed ID: 26912553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factor 23, Klotho, and disordered mineral metabolism in chronic kidney disease: unraveling the intricate tapestry of events and implications for therapy.
    Gutiérrez OM
    J Ren Nutr; 2013 May; 23(3):250-4. PubMed ID: 23611556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parathyroid Hormone, Fibroblast Growth Factor 23, and Parameters of Phosphate Reabsorption.
    Phelps KR; Mason DL
    Am J Nephrol; 2018; 47(5):343-351. PubMed ID: 29779023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.
    Bech AP; Bouma-de Krijger A; van Zuilen AD; Bots ML; van den Brand JA; Blankestijn PJ; Wetzels JF; Vervloet MG
    J Nephrol; 2015 Aug; 28(4):477-84. PubMed ID: 25700931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD.
    Isakova T; Barchi-Chung A; Enfield G; Smith K; Vargas G; Houston J; Xie H; Wahl P; Schiavenato E; Dosch A; Gutiérrez OM; Diego J; Lenz O; Contreras G; Mendez A; Weiner RB; Wolf M
    Clin J Am Soc Nephrol; 2013 Jun; 8(6):1009-18. PubMed ID: 23471131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study.
    Gutiérrez OM; Wolf M; Taylor EN
    Clin J Am Soc Nephrol; 2011 Dec; 6(12):2871-8. PubMed ID: 22034506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.